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One of the strategic objectives of the 2011–2020 Global Vaccine Action Plan is for the benefits of immu-
nisation to be equitably extended to all people. This approach encompasses special groups at increased
risk of vaccine-preventable diseases, such as preterm infants and pregnant women, as well as those with
chronic and immune-compromising medical conditions or at increased risk of disease due to immunose-
nescence. Despite demonstrations of effectiveness and safety, vaccine uptake in these special groups is
frequently lower than expected, even in developed countries with vaccination strategies in place. For
example, uptake of the influenza vaccine in pregnancy rarely exceeds 50% in developed countries and,
although data are scarce, it appears that only half of preterm infants are up-to-date with routine paedi-
atric vaccinations. Many people with chronic medical conditions or who are immunocompromised due to
disease or aging are also under-vaccinated. In the US, coverage among people aged 65 years or older was
67% for the influenza vaccine in the 2014–2015 season and 55–60% for tetanus and pneumococcal vac-
cines in 2013, while the coverage rate for herpes zoster vaccination among those aged 60 years or older
was only 24%. In most other countries, rates are far lower. Reasons for under-vaccination of special
groups include fear of adverse outcomes or illness caused by the vaccine, the inconvenience (and in some
settings, cost) of vaccination and lack of awareness of the need for vaccination or national recommenda-
tions. There is also evidence that healthcare providers’ attitudes towards vaccination are among the most
important influences on the decision to vaccinate. It is clear that physicians’ adherence to recommenda-
tions needs to be improved, particularly where patients receive care from multiple subspecialists and
receive little or no care from primary care providers.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
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One of the strategic objectives of the 2011–2020 Global Vaccine
Action Plan (GVAP) is for the benefits of immunisation to be equi-
tably extended to all people [1]. This approach encompasses spe-
cial groups at increased risk of vaccine-preventable disease, such
as preterm infants and pregnant women, as well as those with
chronic and immune-compromising medical conditions. The
increased risk of disease due to immunosenescence with advanc-
ing age must also be taken into consideration in the development
of vaccination strategies that cover all ages and health conditions.
Special populations are often under-vaccinated for various rea-
sons, including lack of awareness of vaccine-preventable diseases
and uncertainty or misconceptions about the safety and efficacy
of vaccination among patients, parents and healthcare providers,
as well as cost and the inability of healthcare systems to ensure
such patients receive recommended vaccines. In this review, we
discuss vaccination strategies in the context of special situations
or conditions that increase vulnerability to disease, focusing
mainly on recommendations of the World Health Organization
(WHO) and the US Centers for Disease Control and Prevention
(CDC) Advisory Committee on Immunisation Practices (ACIP).
Rationales that support recommended vaccination strategies, as
well as barriers to the immunisation of special populations, are
also considered.2. Vaccination in pregnancy
The physiological changes associated with pregnancy can lead
to an elevated risk for severe disease [2] (Box 1). Influenza infec-
tion during pregnancy also has risks for the foetus, including pre-
mature birth, reduced birth weight and an elevated risk of death
[3]. The 2009 influenza pandemic was a timely reminder of the
risks: surveillance data from the US estimated that influenza infec-
tion during pregnancy was associated with a sevenfold increased
risk of hospitalisation and fourfold increased risk of admission to
intensive care units or death when compared to infected non-ox 1
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a In US and England.pregnant women [4]. During the winter of 2009 in Australia and
New Zealand, the proportion of patients with influenza who were
pregnant and admitted to an intensive care unit was nine times
higher than the corresponding proportion in the general popula-
tion [5]. Advisory groups throughout the world have therefore rec-
ommended influenza vaccination for pregnant women, with the
WHO identifying them as a priority group [6,7]. The positive
impact of maternal influenza vaccination is not limited to devel-
oped countries [7]. For example, a randomised controlled trial with
trivalent inactivated influenza vaccine in Bangladesh suggested
maternal vaccination had effectiveness of 63% against confirmed
influenza in infants, with reduction of influenza-like illness in
infants and mothers by 29% and 36%, respectively [8]. Other study
data suggest influenza vaccination was associated with a signifi-
cant decline in the risk of infants being small for gestational age
[9]. However, for countries with very constrained health budgets,
influenza prevention is rarely a priority [10].
Vaccination against tetanus and pertussis is also widely recom-
mended (Table 1). Neonatal tetanus has a very high case fatality
rate and although improved hygiene during birth reduces the risk
of maternal and neonatal tetanus, maternal vaccination has been
critical in reducing the incidence, especially where good quality
perinatal care is not available and home births are frequent [11].
Effectiveness trials demonstrated reductions in neonatal tetanus
of 80%, with declines in mortality of up to 98% after maternal
receipt of two or three vaccine doses [12]. Between 1988 and
2013, the estimated number of deaths due to tetanus among neo-
nates fell from 787,000 to 49,000 globally, which was attributed
mostly to maternal tetanus vaccination [13]. A key component of
this was the establishment of supplementary immunisation activ-
ities, which ensured that as many pregnant women as possible had
access to the vaccine [11].
Pertussis (whooping cough) remains endemic in much of the
world. Infants are especially vulnerable in the early months of life
before vaccination, once protective maternal antibody levels have
waned [14]. Since vaccination of the family to prevent pertussis
transmission (‘cocooning’) has shown little evidence of effective-
ness, health authorities now increasingly advise against theomen
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tus and by foetus to tolerate mother
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Table 1
Vaccines recommended by the World Health Organization (WHO) and US Centers for Disease Control and Prevention Advisory Committee on Immunisation Practices (ACIP) for
specific groups: pregnant women, preterm infants, adolescents with chronic medical conditions and older adults.
Special population Vaccine Recommendation (advisory body)
Pregnant womena Seasonal inactivated
influenza
One dose at any stage of pregnancy (WHO, ACIP)
T or Td All women giving birth and their newborn babies should be protected against tetanus (WHO)
Tdap One dose in countries or settings with high or increasing infant morbidity/mortality from pertussis (WHO)
One dose in each pregnancy (ACIP)
Preterm infants All recommended
paediatric vaccines
Preterm infants who are otherwise healthy should be immunised according to the same vaccination schedule
as used for full-term infants (WHO, ACIP)
Hepatitis B Birth doses given to infants <2 kg should not be counted towards the primary vaccination series because of
the possibility of poor response (WHO, ACIP)
PCV Booster dose in second year of life if received three primary doses before 12 months of age (WHO)
Adolescents with chronic
medical conditions
HPV As for general population (WHO/ACIP) except: Extended duration of catch-up vaccination for
immunocompromised males (ACIP) Increased dosing requirements for immunocompromised females
<15 years (WHO)
Td/Tdap As for general population (WHO/ACIP) except: Consider shorter dosing interval for Tdap for adolescents with
high risk conditions (ACIP)
Meningococcal
conjugate vaccine
As for general population (WHO/ACIP) except: For high-risk conditions (asplenia, complement component
deficiency, HIV), two primary doses and (if asplenia or complement component deficiency) booster dose
every 5 years (ACIP)
Seasonal inactivated
influenza
One dose annually (WHO, ACIP)
Pneumococcal Catch-up with PCV if high-risk condition, e.g., CSF leak, cochlear implant, asplenia, immunocompromised
(ACIP)
One dose of pneumococcal polysaccharide vaccine if high-risk condition and additional dose after 5 years if
asplenia or immunocompromised (ACIP)
Older adultsa Seasonal inactivated
influenza
P65 years of age: one dose annually (WHO, ACIP)b
Tdap/Td P65 years of age: substitute one-time dose of Tdap for Td booster, then boost with Td every 10 years (ACIP)b
Herpes zoster P60 years of age: one dose (ACIP)
Pneumococcal P65 years of age: one dose of PCV and/or pneumococcal polysaccharide vaccine, depending on vaccination
history (ACIP)
Abbreviations: T, tetanus toxoid; d, reduced diphtheria toxoid; ap, reduced acellular pertussis; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; HPV, human
papillomavirus; MenC, meningococcal group C; PCV, pneumococcal conjugate vaccine.
a Other vaccines may be recommended based on risk factors and special circumstances, including hepatitis A, hepatitis B and meningococcal vaccines.
b Also recommended for younger adults.
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2011–2012, some countries began to recommend maternal
vaccination with the tetanus-diphtheria-acellular pertussis (Tdap)
vaccine, to protect against pertussis infection in early infancy [17].
Following an outbreak of pertussis in England in 2012, a study of
26,684 women (64% of whom were vaccinated) indicated that
the vaccine reduced the risk of pertussis in infants by 91% [18].
While the benefits of maternal vaccination with recommended
vaccines are clear, safety concerns have meant that pregnant
women have traditionally been excluded from clinical trials
[19,20]. The data for both tetanus and influenza vaccination there-
fore rest on decades of experience from very large retrospective
cohorts: more than 170 million women of childbearing age have
been vaccinated against tetanus [13], many of them during preg-
nancy, while influenza vaccination is given to millions of pregnant
women annually. Among the estimated 2 million pregnant women
immunised in the US during the 2000–2003 influenza seasons,
only 20 adverse events were reported to the CDC Vaccine Adverse
Event Reporting System, of which 17 were minor injection-site or
systemic reactions [14]. There are fewer data on Td or Tdap uptake,
due to the recent introduction of the vaccine for use during preg-
nancy and the fact that most of the global elimination campaigns
have been carried out with tetanus toxoid vaccine. Nonetheless, a
US study of 26,229 women vaccinated with Tdap matched with
97,265 unvaccinated women found no evidence of an increased
risk of adverse obstetric events apart from a small increased risk
of chorioamnionitis [21]. Similarly, a UK study of maternal pertus-
sis immunisation in 20,074 women found no increased risk for an
extensive predefined list of adverse events related to pregnancy
[22].Despite such evidence, uptake of recommended vaccines among
pregnant women has tended to be lower than expected [23,24]. For
example, in the 2013–14 influenza season, 52% of women in the US
were vaccinated just before or during pregnancy [23], even though
the vaccine is recommended for all pregnant women. Influenza and
pertussis vaccine uptake in pregnancy in England is around 42%
and 60%, respectively [25,26]. The UK has among the highest
coverage rates globally [27], indicating the scale of the problem.
Common reasons for not receiving vaccination include fear of
adverse pregnancy outcomes, the inconvenience (and in some set-
tings, cost) of vaccination, lack of awareness of national recom-
mendations and failure of the healthcare provider to recommend
vaccination [19,23,24]. In low-income countries, pregnant women
are most likely to cite access issues as barriers to vaccination [19].
In countries where access is not a barrier, the healthcare providers’
recommendation and offer of vaccination appears to be the most
influential factor on whether a pregnant woman is vaccinated or
not. As discussed in an accompanying paper [28], healthcare provi-
ders have a central role in enhancing knowledge of vaccine safety
in all patient groups, including pregnant women.3. Vaccination of preterm infants
Infection tends to have more serious consequences in preterm
than in full-term infants, mainly because of immaturity of the
immune system [29] (Box 2). Consequently, preterm and low birth
weight infants have a higher risk of vaccine-preventable diseases,
including those caused by pertussis, Streptococcus pneumoniae
and rotavirus [30–32].
Box 2
Vaccination of preterm infants.
Population  Preterm infants
Reasons for increased risk of disease  Immaturity of the immune system
Diseases most commonly targeted by vaccination  If clinically stable and not in intensive care: same diseases as targeted for general population of infants
 If hospitalised: diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b,
poliovirus, pneumococcal
Reported vaccine uptake ratesa  40–50% not up to date with routine immunisations
Common barriers to vaccination  Physicians’ inadequate knowledge of efficacy and safety of vaccines in this group
 Reluctance to vaccinate during hospitalisation
Unmet vaccination needs  Vaccination against
 Group B Streptococcus
 Respiratory syncytial virus
 Rotavirus when in neonatal intensive care unit
a In US and Australia.
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otherwise healthy are immunised according to the vaccination
schedule used for full-term infants (Table 1). To ensure early pro-
tection, preterm infants should be vaccinated according to their
chronological rather than corrected gestational age and regardless
of birth weight [29], although it may be appropriate to administer
additional vaccine doses to preterm or extremely low birth weight
infants who produce suboptimal vaccine responses. For hepatitis B
vaccination, guidelines recommend that birth doses given to
infants under 2 kg should not be counted towards the primary vac-
cination series because of the possibility of a poor response [6,33].
Similarly, since a pneumococcal conjugate vaccine (PCV) booster
dose is not administered in all countries [34], WHO guidelines
specifically recommend a booster dose in the second year of life
for preterm infants who received three primary doses before
12 months of age [6] (Table 1).
Preterm infants are usually adequately protected by routine
paediatric vaccines, with immune responses lower than in full-
term infants but high enough to provide protection [29]. In a study
of the 10-valent PCV (SynflorixTM, GSK Vaccines, Belgium),
prevaccination antibody concentrations tended to be higher for
most vaccine pneumococcal serotypes in the term versus preterm
groups [35]. However, after three-dose primary vaccination at
2–4–6 months of age and a booster dose at 16–18 months, at least
98% of children in all term and preterm groups reached the protec-
tive antibody threshold for each vaccine pneumococcal serotype.
Despite demonstrations of protective immune responses, rou-
tine immunisation of premature infants is often delayed because
of physicians’ inadequate knowledge of the immunogenicity or
safety of vaccines. For example, in an audit undertaken in Mel-
bourne, Australia, the 6-month Tdap and poliovirus vaccine doses
were delayed by more than one month in 43% of preterm infants
and uptake of additional recommended vaccine doses was
19–35% [36]. An education programme for healthcare professionals
regarding guidelines was introduced as well as immunisation
‘stickers’ for health records of preterm infants [37]. In an audit con-
ducted four years later, 96% of preterm-born children were up to
date with routine immunisations at 12 months of age and receipt
of additional recommended hepatitis B and influenza vaccines
increased by more than twofold. Also, vaccination of preterm
infants may be discouraged during hospitalisation, as has been
the case for rotavirus vaccination of infants in neonatal intensive
care units (NICUs) [38]. Since the ACIP recommends immunisation
at the time of discharge if the child is clinically stable and aged
42–104 days, preterm infants who remain in the NICU beyond
the upper age limit are ineligible for rotavirus vaccination [39].
However, rotavirus vaccination within the NICU has been shown
to be well tolerated, with no evidence of transmission to contacts
[38,40], indicating that the risk of severe disease in unvaccinated
infants outweighs the risk of transmission during hospitalisation.Despite this, a study of six NICUs in California found that only
51% of discharged infants were up-to-date for vaccines recom-
mended for use in the NICU (Tdap, hepatitis B, Haemophilus influen-
zae type b [Hib] and poliovirus vaccines) [41]. These examples
highlight the need for further demonstrations of vaccination bene-
fits for preterm infants and for alternative approaches to ensure
they receive age-appropriate recommended vaccines.4. Vaccination of individuals with immune-compromising
diseases or other chronic conditions
The number of patients who are immunocompromised or live
with chronic conditions is increasing [42]. Immunocompromised
patients include those with primary (hereditary or genetic)
immunodeficiency disorders or secondary immunodeficiencies
that are generally acquired and occur due to a disease process or
its therapy (Table 2). This includes human immunodeficiency virus
(HIV) infection, cancer, transplantation, asplenia or sickle cell dis-
ease and autoimmune inflammatory diseases treated with
immunosuppressive medications (corticosteroid therapy,
immunomodulatory medications or biological agents) [43–46].
Other populations with chronic conditions may be generally
immunocompetent but at elevated risk for certain vaccine-
preventable infections. Examples include individuals with diabetes
[47], cystic fibrosis [48] or anatomic barrier defects, such as those
with cochlear implants [43]. In cystic fibrosis, it is especially
important to avoid diseases that could cause pulmonary deteriora-
tion, such as pneumonia and influenza [48], while bacterial menin-
gitis is a particular concern for cochlear implant recipients [49].
Among the immunocompromised population, the severity of
immunosuppression varies depending on the condition and treat-
ment drugs used. Thus HIV-infected patients with a CD4 T-cell
count under 200 cells/mm3 (for adults), advanced Hodgkin’s dis-
ease patients and haematopoietic stem cell transplant recipients
rank amongst the most immunocompromised groups [42,43],
whereas those treated with biological agents for multiple sclerosis,
inflammatory bowel disease and rheumatoid arthritis are usually
moderately compromised [44,45,50]. The type of immune defi-
ciency also varies according to underlying disease, e.g., leukaemic
patients may suffer from the effects of neutropenia, HIV/AIDS
patients from T-cell deficiencies, while those with some congenital
immunodeficiencies from B-cell defects.
These factors influence the infections to which immunocompro-
mised patients are predisposed and choice of immunisation strat-
egy. For example, reactivation of herpesviruses is a classic
complication of solid organ and haematopoietic stem cell trans-
plantation [51]. Live attenuated vaccines cannot be used in
severely immunocompromised patients because of the risk of
inducing disease but may be safe in mild or moderately immuno-
Table 2
Effectiveness of vaccination in persons with primary (hereditary or genetic) and secondary (acquired) immunodeficiencies (adapted from ACIP General Recommendations on
Immunisation [46]).
Immunodeficiency Specific immunodeficiency/condition Effectiveness of vaccinationa
Primary
B cell (humoral) Severe antibody deficiencies (e.g., X-linked
agammaglobulinaemia and common variable
immunodeficiency)
The effectiveness of any vaccine is uncertain if it depends only on the humoral
response (e.g., PPSV or MPSV4) IGIV interferes with the immune response to measles
vaccine and possibly varicella vaccine
Less severe antibody deficiencies (e.g., selective IgA
deficiency and IgG subclass deficiency)
All vaccines likely effective; immune response might be attenuated
T cell (cell-mediated
and humoral)
Complete defects (e.g., severe combined
immunodeficiency disease, complete DiGeorge
syndrome)
Vaccines might be ineffective
Partial defects (e.g., most patients with DiGeorge
syndrome, Wiskott-Aldrich syndrome, ataxia-
telangiectasia)
Effectiveness of any vaccine depends on degree of immune suppression
Complement Persistent complement, properdin or factor B
deficiency
All routine vaccines likely effective
Phagocytic function Chronic granulomatous disease, leukocyte adhesion
defect, myeloperoxidase deficiency
All inactivated vaccines likely effective Live viral vaccines likely effective
Secondary
HIV infected MMR, varicella, rotavirus and all inactivated vaccines, including inactivated
influenza, might be effective
Malignant neoplasm, transplantation,
immunosuppressive or radiation therapy
Effectiveness of any vaccine depends on degree of immune suppression
Asplenia or sickle cell diseases All routine vaccines likely effective
Chronic renal disease All routine vaccines likely effective
Abbreviations: HIV, human immunodeficiency virus; Ig, immunoglobulin; IGIV, immune globulin intravenous; MMR, measles, mumps and rubella vaccine; MPSV4,
quadrivalent meningococcal polysaccharide vaccine; PPSV, pneumococcal polysaccharide vaccine.
a See Table 3 for the Infectious Diseases Society of America list of recommended and contraindicated vaccines.
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best alternative although in some cases live attenuated vaccines
can be administered up to a month before patients are predicted
to become immunocompromised [43]. There is much ongoing
research on vaccination of this group, particularly those with sev-
ere T-cell-mediated immunodeficiencies, partly guided by recent
successes with immunotherapy [52,53]. This includes vaccines
against diseases caused by herpesviruses and polyomaviruses,
especially in transplant patients, tuberculosis in HIV-induced
immunodeficiency and for herpes zoster and fungi in haematopoi-
etic stem cell transplantation.
The Infectious Diseases Society of America clinical practice
guideline for vaccination of immunocompromised patients is sum-
marised in Table 3 [43]. This demonstrates the range of approaches
required for the wide variety of conditions involved. We briefly
outline issues involved with two conditions: asplenia, a condition
with a high risk of infectious disease and clear recommendations
for vaccination, and diabetes, an at-risk condition that is frequently
under-vaccinated.
Asplenia results from surgical removal of the spleen or atrophy,
for example following trauma, splenic artery thrombosis, hyper-
splenism (e.g., after schistosomiasis) or recurrent infarctions (e.g.,
in sickle cell disease). Since encapsulated bacteria are primarily
removed by the spleen, hypo- or asplenic patients are susceptible
to severe, often fulminant, infections with encapsulated bacteria,
particularly S. pneumoniae, but also Neisseria meningitidis and Hib
[54,55]. Consequently, current guidelines for hypo- and asplenic
patients emphasise that, in addition to routine vaccination, this
group should be immunised against pneumococcal, meningococcal
and Hib infection as well as against influenza linked to the associ-
ated risk of secondary bacterial infection [54].
In diabetes, immunodeficiency due to genetic and metabolic
abnormalities and other factors (age, renal disease and cardiovas-
cular disease) may account for the increased severity of S. pneumo-
niae and influenza virus infections in this patient group compared
with non-diabetic individuals [56]. Guidelines in various countries
thus recommend influenza and pneumococcal vaccines for thispatient group [57–59]. Epidemiological data from the US suggest
an increased risk for acute hepatitis B among adults with diabetes
[60,61] and chronic hepatitis may have a more severe course in
diabetes patients [62]. Evidence also suggests that diabetes is a risk
factor for herpes zoster [63–65] and post-herpetic neuralgia
[63,64,66]. In 2011, the ACIP recommended hepatitis B vaccination
for previously unvaccinated adults aged 19–59 years with diabetes
as soon as possible after diagnosis and that adults with diabetes
aged 60 years or older are vaccinated at the discretion of the treat-
ing clinician [67]. There is currently no specific recommendation
for vaccinating people with diabetes against herpes zoster.
There are few data on vaccine coverage levels for patients who
are immunocompromised or live with chronic conditions with
increased risks for vaccine-preventable disease. Available evidence
suggests that these patient groups are often under-vaccinated,
even in countries with well-functioning healthcare systems
[44,45,68–70]. For example, a US study of vaccination in patients
with diabetes found coverage rates of 41% for influenza and 37%
for pneumococcal vaccination, while no patients had received the
hepatitis B vaccine despite ACIP guidelines [70]. This may be partly
because of a lack of awareness of the importance of vaccination
and misperceptions about vaccine safety and immunogenicity in
these groups. Patients may miss routine vaccinations because of
frequent hospital admissions and school absenteeism. Also, in cer-
tain countries, such as the US, patients with chronic medical prob-
lems are likely to receive care from a specialist physician rather
than a primary care provider. Vaccinations may therefore be
missed if specialists assume vaccination is the responsibility of a
general practitioner.
4.1. Vaccination of adolescents with chronic medical conditions
Adolescents are an important group to consider separately
because they are at increased risk of several vaccine-preventable
infections, particularly pertussis, human papillomavirus (HPV)
and meningococcal infections [71]. This is due to various factors
including waning immunity to vaccination in the case of pertussis,
Table 3
Vaccines recommended by the Infectious Diseases Society of America (IDSA) for individuals who are immunocompromised because of their condition or treatment of their
condition and contraindicated vaccines (summary of 2013 IDSA clinical practice guideline [43]).
Patient population/condition Recommended vaccines Contraindicated vaccines
Primary immunodeficiency
– Primary (congenital) complement
deficiencies
As for general population None
– Phagocytic cell deficiency Inactivated vaccines, as for general population Live vaccines for majority of patients
– Innate immune defects resulting in
cytokine or cellular activation defects
Inactivated vaccines, as for general population Live vaccines for majority of patients
– Minor antibody deficiencies As for general population OPV for IgA-deficient patients
– Major antibody deficiencies receiving
immunoglobulin therapy or combined
immunodeficiencies
Inactivated influenza vaccine can be administered if residual antibody
production
Inactivated vaccines (other than influenza
vaccine), live vaccines
HIV infected As for general population except for contraindicated vaccines Live attenuated influenza vaccine
Live MMR or VAR for children with CD4 T-cell
percentage <15 or adults/adolescents with CD4
T-cell count <200 cells/mm3
Live MMRV vaccine
Live HZ vaccine
Cancer Inactivated influenza vaccine annually except those receiving anti-B-
cell antibodies or intensive chemotherapy
Live viral vaccines during chemotherapy
Other inactivated vaccines for immunocompetent children receiving
maintenance chemotherapy
PCV followed by PPSV
Three months after chemotherapy or at least 6 months after receiving
anti-B-cell antibodies, can administer inactivated vaccines and live
VAR, MMR, MMRV vaccines as for general population
Haematopoietic stem cell transplant Pre-transplant: As for general population if not immunosuppressed
and if interval to start of conditioning regimen is P4 weeks for live
vaccines andP2 weeks for inactivated vaccines. VAR for nonimmune
transplant candidates if interval to start of conditioning regimen is
P4 weeks
Live vaccines if <4 weeks and inactivated
vaccines if <2 weeks before start of conditioning
regimen
After transplant: live vaccines to patients with
active graft vs host disease or ongoing
immunosuppressionStarting 6 months after transplant: inactivated influenza vaccine, Td-
containing vaccine
Starting 3–6 months after transplant: PCV/PPSV
Starting 6–12 months after transplant: Hib, meningococcal conjugate,
hepatitis B, IPV, HPV vaccines
Starting 24 months after transplant: MMR if measles-seronegative
and VAR if varicella-seronegative and no graft vs host disease or
ongoing immunosuppression
Solid organ transplant Pre-transplant: As for general population, PCV/PPSV, hepatitis B,
hepatitis A, HPV (age 11–26 years) vaccines. MMR and VAR (age 6–
11 months) if not receiving immunosuppression and >4 weeks to
transplant. HZ (age 50–59 years) if not severely
immunocompromised and >4 weeks to transplant
No vaccines in first 2-month period post-
transplant, apart from influenza vaccine if
necessary
MMR, VAR should generally not be administered
to transplant recipients, except VAR in non-
immune children who are renal or liver
transplant recipients and receiving minimal or
no immunosuppression
Starting P1 month after transplant: inactivated influenza vaccine if
disease outbreak
Starting 2–6 months after transplant: As for general population. If not
administered before transplant, PCV with timing based on degree of
immunosuppression
2–6 months after liver transplant: hepatitis B vaccine
Chronic inflammatory diseases on
immunosuppressive medications
As for general population: inactivated vaccines, PCV/PPSV Live vaccines LAIV, MMR, MMRV
VAR if non-immune and P4 weeks to immunosuppression initiation
or if low-level, long-term immunosuppression
HZ (ageP60 years or 50–59 years and varicella-seropositive) if before
immunosuppression initiation or low-dose immunosuppression
Asplenia or sickle cell disease As for general population aged <2 years, including PCV LAIV
If aged P2 years, PCV/PPSV
If aged P5 years, Hib vaccine
If aged P2 months, meningococcal vaccine but not quadrivalent
conjugate vaccine in patients aged <2 years because of reduced
antibody response to PCV when co-administered. If aged P55 years,
revaccination with quadrivalent vaccine every 5 years
Anatomic barrier defects at risk of vaccine-
preventable infection
As for general population: Adults and children with profound
deafness scheduled to receive cochlear implant, congenital dysplasias
of the inner ear or persistent CSF communication with oropharynx or
nasopharynx
None
Patients with orP2 weeks before cochlear implant or with persistent
CSF communication with oropharynx or nasopharynx: PCV/PPSV
Abbreviations: CSF, cerebrospinal fluid; Hib, Haemophilus influenzae type b vaccine; HIV, human immunodeficiency virus; HPV, human papillomavirus vaccine; HZ, herpes
zoster vaccine; Ig, immunoglobulin; IPV, inactivated poliovirus vaccine; LAIV, live attenuated influenza vaccine; MMR, measles, mumps and rubella vaccine; MMRV, MMR-
varicella vaccine; OPV, oral poliovirus vaccine; PCV, pneumococcal conjugate vaccine; PPSV, pneumococcal polysaccharide vaccine; Td, tetanus toxoid, reduced diphtheria
toxoid; VAR, varicella vaccine.
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infections. For the latter, vaccination is available against HPV and
there are several promising vaccine candidates against sexually-
transmitted herpes and chlamydia infections [72]. As described
previously, the presence of chronic medical conditions may
increase the risk of infection and associated complications. The
number of adolescents with chronic medical conditions has
increased in recent decades because of improving survival rates
(e.g., for those with cystic fibrosis, congenital heart disease, cancer
and spina bifida) and a rise in conditions such as HIV/AIDS and dia-
betes [73].
Current WHO and ACIP vaccine recommendations for adoles-
cents with chronic medical conditions were reviewed recently by
Hofstetter et al. [74]. These include HPV, Td/Tdap, meningococcal,
pneumococcal and influenza vaccines [6,75] (Table 1). Conditions
such as cancer, transplantation, HIV infection and systemic lupus
erythematosus increase the risk of HPV infection and related com-
plications [74]. Adolescents with severe chronic medical conditions
also appear to be at increased risk of death following pertussis
infection [76], supporting the ACIP recommendation of a shorter
dosing interval for Tdap vaccination for this group [75]. The
WHO and ACIP both recommend meningococcal vaccination of
individuals with high-risk conditions beginning in early childhood
[77,78], based on evidence that complement component deficien-
cies and asplenia increase susceptibility to meningococcal
infection.
Certain chronic medical conditions (such as pulmonary, cardiac
and neurological or neuromuscular diseases) place adolescents at
increased risk of influenza-related complications, hospitalisation
and death [74]. The ACIP now also recommends pneumococcal
vaccination for children aged 6–18 years who have certain under-
lying conditions [75], supported by data showing that invasive
pneumococcal disease is markedly elevated in this age group if
haematologic malignancy, HIV/AIDS or sickle cell disease is present
[79].
Where reported, vaccination coverage rates among adolescents
with chronic medical conditions are variable but often low, lagging
behind that for younger age groups [74]. For example, two studies
of adolescent cancer survivors in the US found that only around
one-third had received at least one HPV vaccine dose [80,81]. In
England and Wales, the proportion of at-risk 15–19 year-olds
who received pneumococcal vaccination ranged from less than
5% to approximately 65%, depending on the underlying medical
condition [82]. Reasons for under-vaccination of individuals withBox 3
Vaccination of older adults.
Population  Older adults
Reasons for increased risk of disease  Decline in innat
Diseases most commonly targeted by vaccination  Influenza
 Community-acq
 Shingles (herpes
 Tetanus
 Diphtheria
 Pertussis
Reported vaccine uptake ratesa  50–70% for influ
 <25% for herpes
Common barriers to vaccination  Attitudes and be
 Failure of health
 Lack of knowled
 Perceived suscep
 Lack of awarene
Unmet vaccination needs  Vaccines with im
 Vaccines against
Clostridium diffic
 Among active ol
travel-associated
a In US.at-risk conditions in general also apply to the adolescent subgroup,
such as misperceptions of the seriousness as well as risk of
vaccine-preventable diseases and suboptimal coordination of pri-
mary and subspecialty care. Factors that uniquely affect adoles-
cents with chronic medical conditions include the parental role
in making vaccination decisions, often in the face of great complex-
ity in terms of their child’s condition and treatment regimens [74].
Logistical problems are frequently identified by parents as a reason
for delayed or missed vaccinations [83]. Also, because of limited
understanding of and comfort with adolescent health issues,
healthcare providers may fail to provide preventive services to
those with chronic medical conditions [84]. Interventions therefore
need to be tailored to address the barriers to vaccination for these
high-risk patients [74], including strategies to educate adolescents,
parents and healthcare providers about vaccine-preventable dis-
eases and improve provider-family communication [85].5. Vaccination of older adults
Immunosenescence describes the decline in systemic immunity
associated with aging involving both innate and adaptive immune
responses [86]. Older adults are therefore typically more suscepti-
ble to vaccine-preventable diseases and disease can be more severe
than in younger people (Box 3). This is a global problem and the
WHO recommends annual vaccination of persons aged 65 years
or older with seasonal inactivated influenza vaccine [6], while
the ACIP recommends the following additional vaccines: Td/Tdap,
herpes zoster and pneumococcal vaccines [87] (Table 1).
When vaccine strains closely match circulating influenza
viruses, protection rates with inactivated influenza vaccines in
individuals younger than 65 years are typically 70–90% [88]. In
older people, the effectiveness of influenza vaccination is reduced,
irrespective of setting, population and study design, though it
remains the most efficacious public health tool available to protect
elderly individuals against influenza. Attempts to improve effec-
tiveness for people aged over 65 include the introduction in some
countries of inactivated influenza formulations adjuvanted with an
oil-in-water emulsion (MF59) or with increased antigen concentra-
tion as well as quadrivalent vaccines that potentially offer wider
protection [88].
S. pneumoniae is a common cause of community-acquired pneu-
monia in people aged over 65 years, with higher morbidity and
mortality than in younger individuals [89]. The ACIP has recentlye and adaptive (antibody and T-cell) immune responses (immunosenescence)
uired pneumonia
zoster)
enza, tetanus, pneumococcus
zoster
liefs regarding vaccination (especially negative attitudes)
care provider to recommend vaccination
ge of vaccine safety and effectiveness
tibility to disease
ss of national recommendations
proved immunogenicity, particularly influenza and pneumococcal vaccines
other leading causes of infection in older adults, such as Staphylococcus aureus,
ile
der adults, better consideration should be given to immunity to and risk of
diseases
6688 M. Doherty et al. / Vaccine 34 (2016) 6681–6690recommended routine use of both pneumococcal conjugate and
polysaccharide vaccines for adults in this age group [90], based
on evidence from a randomised controlled trial with the 13-
valent PCV [91]. Age-related declines in T-cell immunity are also
predictive of an increased incidence and severity of herpes zoster
[92,93]. The large Shingles Prevention Study showed efficacy with
a concentrated live attenuated vaccine (ZostavaxTM, Merck & Co,
Inc., US) against herpes zoster and post-herpetic neuralgia in adults
aged 60 years or older [94]. However, its efficacy against the occur-
rence of herpes zoster decreased with age, falling to 38% in adults
aged 70 years or older [94], and protection ceased to be significant
after eight years [95]. It is licensed for immunocompetent adults
aged 60 years or older in many countries [96]. A new investiga-
tional herpes zoster subunit vaccine that combines a key virus sur-
face glycoprotein with a T-cell boosting GSK proprietary adjuvant
system (ASO1B) showed efficacy of over 90% in 50–59, 60–69
andP 70 years age groups in a randomised controlled trial [97,98].
Vaccination coverage rates for older adults show targets are
often not being reached. The global target for influenza vaccination
coverage is at least 75% for persons aged 65 years or older, but this
has been achieved in few countries [99]. In the US, influenza vac-
cine coverage in the 2014–2015 season was 67% for this age group
[100]; coverage for other vaccines in 2013 was 56% for tetanus, 60%
for pneumococcus and (in adults aged 60 years or older) 24% for
herpes zoster [101]. In developed economies, the most important
factors related to vaccine uptake among older adults are people’s
attitudes and beliefs regarding vaccination, recommendations of
healthcare providers, vaccine safety and effectiveness, and per-
ceived susceptibility to disease [102]. Also, older adults may be
unaware of the need for vaccination because of a lack of commit-
ment from national health systems to fully implement vaccine rec-
ommendations [103]. Uptake rates may be improved with public
education campaigns, by introducing appropriate operational
frameworks and by introducing new vaccine formulations that
enhance immune responses with additional adjuvants, increased
dose or other changes in vaccine composition [104]. In particular,
the development of more immunogenic influenza and pneumococ-
cal vaccines of broader specificity is actively being pursued. In
developing countries, the need for better vaccination coverage of
aging populations is recognised [105] and influenza vaccine effec-
tiveness appears to be similar to that reported in high-income
countries [106], but developing countries struggle to implement
WHO recommendations on influenza vaccination [107].6. Conclusions
To achieve one of the strategic objectives set by the GVAP – to
equitably extend the benefits of immunisation to all people – every
eligible individual should be immunised with all appropriate vac-
cines [1]. The Pan American Health Organization has also promoted
a complete transition from child to family immunisation pro-
grammes, in which countries incorporate into their national sched-
ules appropriate vaccines for all family members throughout their
lives [108]. Consistent with these objectives, target populations for
vaccination encompass special populations who are especially vul-
nerable to vaccine-preventable infections, including pregnant
women, preterm infants, people with chronic and immune-
compromising conditions and older adults.
It is clear that special groups are often under-vaccinated due to a
variety of reasons, including lack of awareness of vaccine-
preventable diseases and healthcare systems that fail to ensure
such patients receive recommended vaccines. This is particularly
applicable to conditions where patients receive care from multiple
subspecialists and little or no care from primary care providers. To
reach the unvaccinated, there is a need for greater awarenessamong patients, caregivers and healthcare providers of the value
of vaccines and vulnerability to vaccine-preventable diseases at dif-
ferent ages or in association with different health conditions. There
is an obvious need for improved understanding of basic aspects of
vaccines among special populations and the healthcare profession-
als involved in their care, including the specific immunopathogen-
esis of target diseases, the epidemiology of vaccine-preventable
infections, effects of vaccines and optimal timing of recommended
immunisation. There is also evidence that healthcare providers’
attitudes towards vaccination are among the most important influ-
ences on the decision to vaccinate but that physicians’ adherence to
recommendations needs to be improved. The fact that vaccination
rates among at-risk populations remain low despite recommenda-
tions indicates a continuing failure to provide appropriate stan-
dards of care. Reversing this is likely to require a broad range of
interventions. Financial incentives, patient reminders and patient
recall systems all appear to improve vaccination rates and can be
more readily implemented in high income country settings
[109,110]. The data from low and middle income countries are less
robust but suggest that patient reminders and immunisation out-
reach could work in these settings also [111–113].
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